CSPC Pharmaceutical (HKG:1093) granted an exclusive license to Cipla USA to sell its irinotecan liposome injection in the US, according to a Thursday filing with the Hong Kong bourse.
The injection is indicated for the treatment of multiple solid tumors such as metastatic pancreatic cancer, colorectal cancer, lung cancer, and cervical cancer, the filing said.
Under the agreement, CSPC Pharma will get an upfront payment of $15 million and may be eligible to obtain up to $25 million in potential first commercial sale and regulatory milestone payments.
CSPC could also receive up to $1.03 billion in additional commercial sales milestone payments, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。